State Newborn Screening Policies Cut Infant Cardiac Deaths

Share this content:
State Newborn Screening Policies Cut Infant Cardiac Deaths
State Newborn Screening Policies Cut Infant Cardiac Deaths

TUESDAY, Dec. 5, 2017 (HealthDay News) -- Implementation of state newborn screening policies for critical congenital heart disease is associated with a decrease in infant cardiac deaths, according to a study published in the Dec. 5 issue of the Journal of the American Medical Association.

Rahi Abouk, Ph.D., from William Paterson University in Wayne, N.J., and colleagues examined the correlation between implementation of state newborn screening policies for critical congenital heart disease and infant death rates. Data were analyzed from the National Center for Health Statistics' period linked birth/infant death data set files for 2007 to 2013 for 26,546,503 U.S. births through June 30, 2013.

There were 2,734 deaths due to critical congenital heart disease and 3,867 deaths due to other/unspecified causes between 2007 and 2013. The researchers found that in states with mandatory screening policies, critical congenital heart disease death rates were 8.0 per 100,000 births in 2007 and 6.4 per 100,000 births in 2013; the death rates for other/unspecified cardiac causes were 11.7 and 10.3 per 100,000 births in 2007 and 2013, respectively. There was a 33.4 percent decrease in early infant deaths from critical congenital heart disease through Dec. 31, 2013. Early infant deaths from other/unspecified cardiac causes decreased by 21.4 percent.

"Statewide implementation of mandatory policies for newborn screening for critical congenital heart disease was associated with a significant decrease in infant cardiac deaths between 2007 and 2013 compared with states without these policies," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »